Inhibiting hepatitis C's nonstructural 5A, or NS5A, protein causes viral levels to drop by 99 percent within six hours of administration, and in one clinical trial, it led to sustained drops in viral levels in all treated patients – a stunning validation of the possibility of developing an all-oral hepatitis treatment regimen.